Leukemia & Lymphoma Society to Give Epizyme Inc. $7.5M

According to multiple reports, Epizyme Inc., a Cambridge firm which primarily specializes in personalized cancer therapeutics, is in line to receive as much as $7.5 million in milestone payments from the Leukemia & Lymphoma Society. The payment, apparently, is for the development of the company’s DOT1L-targeted histone methyltransferase inhibitor for Mixed Lineage Leukemia (MLL) – a blood cancer clot that hits people of all ages.

Reportedly, the funding will take care of Epizyme’s development of the treatment through Phase 1 trials, with a wait-and-see approach being taken from that point on. Epizyme, of course, develops personalized treatments for various forms of cancers and diseases that mostly rely on small molecule inhibitors of histone methyltransferase.

Back in March, Epizyme announced that they had partnered up with Japanese firm Eisai Co. Ltd. in a deal that supposedly had the power to bring in more than $200 million. The deal was based on the development and commercialization of treatments that were supposed to deal with the epigenetic enzyme, EZh4, for lymphoma and genetically-defined cancers.

Also, in January, Epizyme formed a development and commercialization alliance with GlaxoSmithKline in a deal that was estimated to be worth over $630 million milestone payments.

More Articles

More Articles

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

It is nearly impossible to talk about a survival rate for...

Lymphosarcoma is a malignant tumor (or tumors) derived from lymphoid tissue (lymph nodes, tonsils, thymus, spleen, etc.). It is an illness that...

Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive Non-Hodgkin’s Lymphoma (NHL) that occurs in B-cells....

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A lymphoma diagnosis is not difficult to determine once a patient and doctor begin to look for signs of cancer...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphoma is a general term for cancer in the lymph system. The lymph system is made up of many cells and organs, including the lymph nodes, thymus...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...